These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 22229849)

  • 1. Targeted therapies and predictive markers in epithelial malignancies of the gastrointestinal tract.
    McIntire M; Redston M
    Arch Pathol Lab Med; 2012 May; 136(5):496-503. PubMed ID: 22229849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
    Cervera P; Fléjou JF
    Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of response to targeted therapies for gastrointestinal stromal tumors.
    Marrari A; Wagner AJ; Hornick JL
    Arch Pathol Lab Med; 2012 May; 136(5):483-9. PubMed ID: 22229850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies in gastrointestinal cancers.
    Bronte G; Cicero G; Cusenza S; Galvano A; Musso E; Rizzo S; Sortino G; Roselli M; Bazan V; Fiorentino E; Russo A
    Expert Opin Biol Ther; 2013 Jun; 13(6):889-900. PubMed ID: 23441760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC.
    Hirsch FR
    Oncogene; 2009 Aug; 28 Suppl 1():S1-3. PubMed ID: 19680291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors to targeted treatment in gastrointestinal carcinomas.
    Silvestris N; Marech I; Brunetti AE; Azzariti A; Numico G; Cicero G; Delcuratolo S; De Luca R; Burz C; Lorusso V
    Cancer Biomark; 2014; 14(2-3):151-62. PubMed ID: 24878816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of response to targeted therapy in renal cell carcinoma.
    Eisengart LJ; MacVicar GR; Yang XJ
    Arch Pathol Lab Med; 2012 May; 136(5):490-5. PubMed ID: 22229848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T; Liu G; Tsao MS
    Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular predictors of response to chemotherapy in colorectal cancer.
    Dienstmann R; Vilar E; Tabernero J
    Cancer J; 2011; 17(2):114-26. PubMed ID: 21427555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in cancer chemotherapy with special stress on molecular-targeted therapy.
    Saijo N
    Jpn J Clin Oncol; 2010 Sep; 40(9):855-62. PubMed ID: 20651047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy.
    Savonarola A; Palmirotta R; Guadagni F; Silvestris F
    Pharmacogenomics J; 2012 Aug; 12(4):277-86. PubMed ID: 22760589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Array-based pharmacogenomics of molecular-targeted therapies in oncology.
    Sanoudou D; Mountzios G; Arvanitis DA; Pectasides D
    Pharmacogenomics J; 2012 Jun; 12(3):185-96. PubMed ID: 22249357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Predictive and prognostic factors in the neoadjuvant/adjuvant therapy of gastrointestinal tumors: wishful thinking or reality?].
    Vallböhmer D; Lenz HJ
    Zentralbl Chir; 2006 Apr; 131(2):148-56. PubMed ID: 16612782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies.
    Stella GM; Luisetti M; Inghilleri S; Cemmi F; Scabini R; Zorzetto M; Pozzi E
    Respir Med; 2012 Feb; 106(2):173-83. PubMed ID: 22104541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
    Shigematsu H; Takahashi T; Nomura M; Majmudar K; Suzuki M; Lee H; Wistuba II; Fong KM; Toyooka S; Shimizu N; Fujisawa T; Minna JD; Gazdar AF
    Cancer Res; 2005 Mar; 65(5):1642-6. PubMed ID: 15753357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.
    Gilbert JA; Adhikari LJ; Lloyd RV; Rubin J; Haluska P; Carboni JM; Gottardis MM; Ames MM
    Endocr Relat Cancer; 2010 Sep; 17(3):623-36. PubMed ID: 20385747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C; Vidal L; Siu LL
    Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors.
    Sartori G; Cavazza A; Sgambato A; Marchioni A; Barbieri F; Longo L; Bavieri M; Murer B; Meschiari E; Tamberi S; Cadioli A; Luppi F; Migaldi M; Rossi G
    Am J Clin Pathol; 2009 Apr; 131(4):478-89. PubMed ID: 19289583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies.
    Cappetta A; Lonardi S; Pastorelli D; Bergamo F; Lombardi G; Zagonel V
    Crit Rev Oncol Hematol; 2012 Jan; 81(1):38-48. PubMed ID: 21256046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic alterations as the basis for resistance to targeted therapies.
    Blair BG; Bardelli A; Park BH
    J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.